Teva Pharmaceuticals, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2023 | KY-AG | $71,477,474 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
Teva | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MD-AG | $70,281,867 |
AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | $68,500,000 |
Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2023 | WV-AG | $68,000,000 |
Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Endo Health Solutions and Endo Pharmaceuticals | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $60,000,000 |
eBay Inc. | eBay | retailing | Controlled Substances Act violation | 2024 | DOJ_CIVIL | $59,000,000 |
Kroger Co. | Kroger | retailing | off-label or unapproved promotion of medical products | 2022 | NM-AG | $58,500,000 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | FDA | $56,500,000 |
Walmart | Walmart | retailing | off-label or unapproved promotion of medical products | 2024 | MD-AG | $55,473,855 |
Omnicare, Inc. | CVS Health | retailing | Controlled Substances Act violation | 2012 | DEA | $50,000,000 |
Endo Health Solutions | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | NY-AG | $50,000,000 |
Dunn Meadow LLC | | | Controlled Substances Act violation | 2022 | USAO | $50,000,000 |
Allergan PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2023 | KY-AG | $48,666,145 |
Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2024 | WA-AG | $47,500,000 |
Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
Centers for Care, LLC | | | nursing home violation | 2024 | NY-AG | $45,000,000 |
K-VA-T Food Stores | K-VA-T Food Stores | retailing | off-label or unapproved promotion of medical products | 2023 | TN-AG | $44,500,000 |
Walmart | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | AL-AG | $44,200,000 |
Elan Corp. | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $43,399,040 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $42,900,000 |
Janssen Pharmaceuticals/Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
CareFusion | Becton Dickinson | medical equipment and supplies | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $40,100,000 |
United Parcel Service | United Parcel Service | freight and logistics | Controlled Substances Act violation | 2013 | USAO | $40,000,000 |
McKinsey & Co. | McKinsey | business services | off-label or unapproved promotion of medical products | 2024 | private lawsuit-federal | $39,500,000 |
Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MD-AG | $38,166,450 |
McKesson Corporation | McKesson | wholesalers | Controlled Substances Act violation | 2019 | WV-AG | $37,000,000 |
InterMune Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
Mallinckrodt LLC | Mallinckrodt | pharmaceuticals | Controlled Substances Act violation | 2017 | DEA | $35,000,000 |
Pfizer | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $35,000,000 |
UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
Cardinal Health | Cardinal Health | wholesalers | Controlled Substances Act violation | 2016 | DEA | $34,000,000 |
Cardinal Health | Cardinal Health | wholesalers | Controlled Substances Act violation | 2008 | USAO | $34,000,000 |
Organon | Organon & Co. | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | $31,000,000 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $29,000,000 |
Healthpoint Ltd. and DFB Pharmaceuticals | | | off-label or unapproved promotion of medical products | 2012 | FDA | $28,000,000 |
Healthpoint Ltd. | | | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $28,000,000 |
Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $27,000,000 |
Teva Parmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $27,000,000 |
Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | CT-AG | $25,100,000 |
Novo Nordisk Inc. | Novo Holdings A/S | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $25,000,000 |
Abbott Laboratories | Abbott Laboratories | pharmaceuticals | off-label or unapproved promotion of medical products | 2018 | USAO | $25,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
McKinsey & Co. | McKinsey | business services | off-label or unapproved promotion of medical products | 2024 | private lawsuit-federal | $23,000,000 |
Par Pharmaceutical Companies Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
CVS Health | CVS Health | retailing | Controlled Substances Act violation | 2015 | USAO | $22,000,000 |
Morris & Dickson Company LLC | | | Controlled Substances Act violation | 2019 | USAO | $22,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | RI-AG | $21,000,000 |
Ascension Texas and Ascension Seton et al. | Ascension Health | healthcare services | HHS civil monetary penalties | 2021 | HHSOIG | $20,983,888 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,786,034 |
Celgene Corp. | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
Jazz Pharmaceuticals Inc. | Jazz Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | USAO | $20,000,000 |
Rochester Drug Co-Operative, Inc. | Rochester Drug Co-Operative | wholesalers | Controlled Substances Act violation | 2019 | USAO | $20,000,000 |
Cardinal Health | Cardinal Health | wholesalers | Controlled Substances Act violation | 2017 | WV-AG | $20,000,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | LA-AG | $20,000,000 |
OptumRx Inc. | UnitedHealth Group | healthcare services | Controlled Substances Act violation | 2024 | DOJ_CIVIL | $20,000,000 |
OptumRx Inc. | UnitedHealth Group | healthcare services | Controlled Substances Act violation | 2024 | DEA | $20,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
Purdue Pharma | Purdue Pharma | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | $19,500,000 |
Genentech Inc. | Roche | pharmaceuticals | off-label or unapproved promotion of medical products | 2000 | MULTI-AG | $19,000,000 |
Morris & Dickson Co., LLC | | | Controlled Substances Act violation | 2024 | DEA | $19,000,000 |
Universal Pharmacy Solutions Inc. | | | Controlled Substances Act violation | 2007 | USAO | $18,773,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | AR-AG | $18,500,000 |
Eli Lilly | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MS-AG | $18,500,000 |
Mariner Health Care, Inc. | | | nursing home violation | 2024 | CA-AG | $17,750,000 |
Florida Men's Medical Clinic, LLC and Men's Medical Clinic, LLC | | | off-label or unapproved promotion of medical products | 2016 | MA-AG | $17,000,000 |
AmerisourceBergen | Cencora Inc. | wholesalers | Controlled Substances Act violation | 2017 | WV-AG | $16,000,000 |
Omnicare Inc. | CVS Health | retailing | Controlled Substances Act violation | 2020 | DEA | $15,300,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MA-AG | $15,100,000 |
GlaxoSmithKline, LLC | GSK plc | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MD-AG | $15,000,000 |
Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $14,750,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $14,500,000 |
Kadlec Regional Medical Center | Providence | healthcare services | HHS civil monetary penalties | 2022 | HHSOIG | $14,351,283 |
Morris & Dickson | | | Controlled Substances Act violation | 2024 | USAO | $13,750,000 |
Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
PeaceHealth | | | healthcare price transparency violation | 2023 | WA-AG | $13,400,000 |
McKesson Corp. | McKesson | wholesalers | Controlled Substances Act violation | 2008 | DOJ_CIVIL | $13,250,000 |
Eli Lilly and Co. | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | ID-AG | $13,000,000 |
King Soopers | Kroger | retailing | Controlled Substances Act violation | 2005 | USAO | $13,000,000 |
Lee Health and Cape Coral Hospital | | | HHS civil monetary penalties | 2022 | HHSOIG | $12,721,886 |
Sandoz, Inc. | Sandoz Group | pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $12,640,000 |
Droguera Betances, LLC | | | Controlled Substances Act violation | 2023 | DOJ_CIVIL | $12,000,000 |
Costco Wholesale | Costco | retailing | Controlled Substances Act violation | 2017 | DEA | $11,750,000 |
Victory Pharma Inc. | | | off-label or unapproved promotion of medical products | 2012 | DOJ_CIVIL | $11,420,743 |
Eisai Inc. | Eisai | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $11,000,000 |
CVS Pharmacy, Inc. | CVS Health | retailing | Controlled Substances Act violation | 2013 | DEA | $11,000,000 |
Cell Therapeutics Inc. | | | off-label or unapproved promotion of medical products | 2007 | FDA | $10,500,000 |
Specialty Distribution Services Inc. | | | off-label or unapproved promotion of medical products | 2007 | USAO | $10,500,000 |
Lincare Inc. | Linde | industrial services | HHS civil monetary penalties | 2006 | HHSOIG | $10,000,000 |
Kinray LLC | Cardinal Health | wholesalers | Controlled Substances Act violation | 2016 | USAO | $10,000,000 |
Endo Pharmaceuticals | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $10,000,000 |
Injured Workers Pharmacy | | | Controlled Substances Act violation | 2023 | USAO | $10,000,000 |
CVS Pharmacy, Inc. | CVS Health | retailing | off-label or unapproved promotion of medical products | 2024 | AK-AG | $10,000,000 |
UCB Inc. | UCB | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $9,893,322 |
Medicis Pharmaceutical Corporation | Bausch Health | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $9,800,000 |
Avalign Technologies Inc. | | | off-label or unapproved promotion of medical products | 2019 | USAO | $9,500,000 |